Knight Therapeutics (Knight Therapeutics Stock Quote, Chart, News, Analysts, Financials TSXV:GUD) is shifting its focus back to Canada with a $41-million deal for domestic assets from Japan’s Sumitomo, a move Stifel analyst Justin Keywood called a positive step toward re-rating the stock in a June 5 note, maintaining a “Buy” rating and C$7.45 target price. […]
Knight Therapeutics (Knight Therapeutics Stock Quote, Chart, News, Analysts, Financials TSXV:GUD) is continuing to build momentum, according to Stifel Nicolaus Canada analyst Justin Keywood, who maintained his “Buy” rating and $7.45 target price following the company’s first-quarter earnings release on May 8. Keywood said Knight is steadily assembling a diversified global portfolio of pharmaceutical assets […]
Share
Tweet
Share
